Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels

Next Previous
Trial Profile

A Phase 1B Dose Escalation Study of AV-380 in Combination With Standard of Care Chemotherapy in Metastatic Cancer Patients With Cachexia and Elevated GDF-15 Levels

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Rilogrotug (Primary)
  • Indications Cachexia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors AVEO Oncology

Most Recent Events

  • 03 Jun 2025 According to an AVEO Oncology media release, data from this trial has been presented as a poster presentation at the upcoming American Society of Clinical Oncology (ASCO) 2025 annual meeting
  • 28 Apr 2025 According to an AVEO Oncology media release, data from this trial will be presented at the upcoming American Society of Clinical Oncology (ASCO) 2025 annual meeting
  • 06 Apr 2025 The protocol has been amended.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top